Montelukast Generics

Montelukast, the active ingredient in Montelukast Generics, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is prescribed to manage asthma and allergic rhinitis in adults and children. GNH USA supplies Montelukast Generics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is used to manage conditions that involve leukotriene‑mediated airway inflammation.

Asthma: improves long‑term control and reduces the frequency of bronchospasm. Allergic rhinitis: relieves nasal congestion, sneezing, itching and rhinorrhea. Exercise‑induced bronchoconstriction: prevents symptoms triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Sore throat - Dizziness

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Mood changes, including suicidal thoughts - Elevated liver enzymes - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Eosinophilic granulomatosis with polyangiitis - Chest pain or palpitations

Before initiating therapy, consider the following precautions.

Monitor mood changes: watch for depression or suicidal ideation. Assess liver function: use cautiously in patients with hepatic impairment. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Review concomitant medications: check for potential drug interactions. Use with caution in severe hepatic disease: dose adjustment may be required. Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with several medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Phenobarbital and other enzyme inducers: may reduce effectiveness. - Rifampin: can lower drug concentrations. - Certain antidepressants (e.g., fluoxetine): may heighten neuropsychiatric risk. - Warfarin: potential alteration of INR.

Moderate Interactions (Monitor Closely): - Phenylephrine or pseudoephedrine: may diminish bronchodilatory benefit. - Beta‑agonists: additive bronchodilation may occur. - NSAIDs: possible increase in bronchospasm risk. - Theophylline: plasma levels may be affected. - Montelukast with other leukotriene modifiers: monitor for overlapping toxicity.